Radiopharm Theranostics Ltd
ASX:RAD
ROA
Return on Assets (ROA) measures how efficiently a company uses its assets to generate profit. It shows how much net income is earned for each dollar of assets.
Return on Assets (ROA) measures how efficiently a company uses its assets to generate profit. It shows how much net income is earned for each dollar of assets.
Peer Comparison
| Country | Company | Market Cap | ROA | ||
|---|---|---|---|---|---|
| AU |
R
|
Radiopharm Theranostics Ltd
ASX:RAD
|
78m AUD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
415.6B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.3B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.7B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.6B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
69.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
39.4B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -3 276.3% |
| 30th Percentile | -27.2% |
| Median | -8.5% |
| 70th Percentile | 0.8% |
| Max | 4 870.2% |
Other Profitability Ratios
Radiopharm Theranostics Ltd
Glance View
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The firm is a developer of platform of radiopharmaceutical products for both diagnostic and therapeutic uses. The company has a pipeline of four licensed platform technologies, namely Nano- monoclonal antibodies (mAbs) technology, Pivalate, AVb6 Integrin and PSA-mAb. Nano-mAbs technology platform provides Nano-mAbs, which are made using genetically engineered camelid derived single domain antibodies (sdAb), that are labelled with radioisotopes to diagnose and treat specific cancers expressing HER-2, TROP-2, PD-L1 and PTK7 receptors. Pivalate is an F-FPIA radiotracer, and its technology is based on a short chain carbohydrate. Its clinical program includes five Phase I clinical trials, five Phase II clinical trials, and two Phase I clinical trials targeting a various cancer, including breast, lung, kidney, head and neck, pancreatic and brain. Its pipeline consists of RAD101, RAD102, RAD104, RAD105, RAD106, and RAD201 among others.
See Also
ROA is calculated by dividing the Net Income by the Avg Total Assets.
The current ROA for Radiopharm Theranostics Ltd is -48.4%, which is above its 3-year median of -55.1%.
Over the last 2 years, Radiopharm Theranostics Ltd’s ROA has decreased from -43.7% to -48.4%. During this period, it reached a low of -65.2% on Jun 30, 2024 and a high of -43.7% on May 30, 2023.
